No Data
No Data
Sunshine Novo (688621): The profit side exceeded expectations and new orders continued to grow at a high rate in the first quarter
Event Overview On April 26, 2024, Sunshine Nuohe disclosed the 2023 Annual Report and 2024 Quarterly Report: The company achieved operating income of 932 million yuan in 2023, an increase of 37.76% over the previous year; achieved net profit to mother
Sunshine Novo (688621): Steady growth in performance and abundant orders to ensure future growth
Steady growth in performance, with abundant orders to guarantee future growth. In 2023, the company achieved operating income of 932 million yuan, an increase of 37.76%; net profit to mother was 185 million yuan, an increase of 18.08% over the previous year; net profit not attributable to mother
Minsheng Securities released a research report on April 27 stating that it gave Sunshine Novo (688621.SH) a recommended rating. The main reasons for the rating include: 1) two-wheel drive for pharmaceutical research and clinical services, continuing to ex
Minsheng Securities released a research report on April 27 stating that it gave Sunshine Novo (688621.SH) a recommended rating. The main reasons for the rating include: 1) two-wheel drive for pharmaceutical research and clinical services, continuing to expand diversified business fields; 2) rapid expansion of independent R&D pipelines, and strong R&D demand from downstream customers. (Mainichi Keizai Shimbun)
Sunshine Novo (688621): Steady growth in performance, positive implementation of self-research results
Event: The company achieved operating income of 932 million yuan, up 37.8% year on year; net profit to mother was 185 million yuan, up 18.1% year on year. Achieved in the first quarter of '24: operating revenue of $252 million, same
Sunshine Novo (688621): Profit side growth in Q1 surpassed expectations, strong demand for one-stop CRO business
Event: On April 25, 2024, Sunshine Nuohe released its 2023 annual report. The company achieved annual revenue of 932 million yuan, a year-on-year increase of 37.76%; net profit to mother was 185 million yuan, an increase of 18.0 million yuan
Pacific released a research report on April 26 stating that it gave Sunshine Novo (688621.SH) a purchase rating. The main reasons for the rating include: 1) strong clinical business growth throughout the year, with 23Q4 sales expenses dragging down profit
Pacific released a research report on April 26 stating that it gave Sunshine Novo (688621.SH) a purchase rating. The main reasons for the rating include: 1) strong clinical business growth throughout the year, with 23Q4 sales expenses dragging down profit growth; 2) continuous increase in R&D investment and continuous expansion of the talent team; 3) high growth in new signings and ongoing orders, and strong certainty about future performance. (Mainichi Keizai Shimbun)
No Data